- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00506688
Efficacy and Safety Study of Inhaled Glutathione in Cystic Fibrosis Patients
Randomized, Placebo-controlled, Double-blinded Study to Investigate the Efficacy and Safety of a 24-week Inhalation Treatment With Glutathione in Cystic Fibrosis Patients
The majority of cystic fibrosis (CF) patients die from a progressive pulmonary disease.Airway inflammation plays a major role for the pathogenesis of CF lung disease, and ultimately leads to lung destruction. The release of oxidants during the inflammation process leads to a chronic imbalance of oxidants and antioxidants and may be a central component leading to irreversible lung damage in CF patients. The antioxidant glutathione, which is a naturally occurring tripeptide, is depleted in the extracellular epithelial lining fluid of the CF lung. The elevation of reduced level to normal and also the augmentation of glutathione concentrations above the normal level, as observed in smokers and during defence of Pseudomonas infection, may be desirable to avoid lung damage. Data from pilot studies in humans and animals have indicated that the glutathione concentrations in epithelial lining fluid can be elevated by aerosol application.
The main objective of this trial is to evaluate the effect of a 24-week treatment with inhaled glutathione compared with control inhalations (normal saline) on pulmonary function in adult and pediatric CF patients. Secondary objectives are to determine the effects of inhaled glutathione on inflammatory variables, glutathione levels and free elastase in induced sputum and to evaluate the safety and tolerability of the 24-week treatment with inhaled GSH.
There is considerable hope within the CF community that the addition of anti-oxidative therapy to an already comprehensive program for treating the lungs will decrease morbidity and improve the quality of life for patients with CF.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany, 13353
- Charité Campus Virchow Klinikum,Klinik für Pädiatrie
-
Bochum, Germany, 44791
- Universitätskinderklinink
-
Cologne, Germany, D-50924
- Uniklinik Köln Mukoviszidose Zentrum
-
Essen, Germany, 45239
- Ruhrlandklinink
-
Essen, Germany, D-45128
- CF-Ambulanz/ Universitätsklinikum Essen
-
Frankfurt, Germany, D-60590
- CF-Ambulanz Frankfurt
-
Freiburg, Germany, 79104
- Universitätsklinikum Freiburg
-
Hamburg, Germany, 22763
- Gemeinschaftspraxis CF Ambulanz
-
Hannover, Germany, 30625
- Med. Hochschule Hannover
-
Hannover, Germany, D-30625
- MHH Kinderklinik CF-Ambulanz
-
Leipzig, Germany, 04109
- Universitätsklinik
-
Munich, Germany, D-80337
- CF-Amulanz/ Dr.von Haunersches Kinderspital
-
München, Germany, 80336
- Klinikum Innenstadt, Medizinische Klinik / Pneumologie
-
Münster, Germany, 48153
- Clemenshospital GmbH,Akademisches Lehrkrankenhaus der Westfälischen Wildhelms-Universität Münster
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female patient, 8 years (pediatric 8 - 17 years inclusive; adult 18 years)
- Confirmed diagnosis of CF (positive sweat chloride, 60 mEq/liter by pilocarpine iontophoresis and/or a genotype with two identifiable mutations consistent with CF accompanied by one or more clinical features with the CF phenotype)
- Patient is able to perform acceptable spirometric maneuvers according to ATS standards
- FEV1 > 40% predicted and < 90% predicted
- The patient is clinically stable fulfilling the following:
No evidence of acute upper or lower respiratory tract infection within 4 weeks of screening.
No pulmonary exacerbation requiring an use of i.v./oral/inhaled antibiotics, or oral corticosteroids within 4 weeks of screening.
FEV1 at Visit 2 is within a range of ± 10% of FEV1 from the Visit 1. (If FEV1 at V2 is not within that range, V2 may be re-scheduled once within 7 days)
- Concomitant or chronic medication is planned to be continued unchanged for the entire study duration
- The patient or the patient's legally acceptable representative is able to give informed consent in accordance with ICH and GCP guidelines and local legislation
- Patient is able to comply with the study visit schedule and willing and able to complete the assessments specified in the protocol.
Exclusion Criteria:
- History of allergy/hypersensitivity (including medication allergy) that is deemed relevant to the trial by the investigator. "Relevance" in this context refers to any increased risk of hypersensitivity reaction to trial medication. (Specific concerns currently identified with respect to the use of inhaled glutathione in allergic patients per se are not existing)
- Concomitant inhaled thiol-containing medications (e.g., inhaled N-acetylcysteine).
Such medication had to be finished at least 2 weeks before the screening visit. Oral N-acetylcysteine may be continued.
- New oral or inhaled thiol-containing medications (e.g., inhaled or oral N-acetylcysteine) throughout the study period.
- Patient with a known relevant substance abuse, including alcohol or drug abuse.
- Pregnant or lactating woman or female patient of child bearing potential who is sexually active and not using a medically approved form of contraception such as oral or injectable contraceptives, intrauterine devices, double-barrier method, contraceptive patch, male partner sterilization or condoms.
- Patient with a documented persistent colonization with B. cepacia (defined as more than one positive culture within the past year).
- Start of a new concomitant or chronic medication for CF within 4 weeks of screening.
- Existing cycling medication regimen without completion of at least 3 cycles prior to the screening visit or the drug cycles of other therapies are not in accordance with the 4-week time-schedule for the single visits of this study
- Clinically relevant diseases or medical conditions other than CF or CF-related conditions that, in the opinion of the investigator, would compromise the safety of the patient or the quality of the data. This includes, but is not limited to, significant hematological, hepatic,renal, cardiovascular, and neurological diseases (diabetic patients may participate if their disease is under good control prior to screening).
- Participation in another study with an investigational drug within one month or 6 halflives(whichever is greater) preceding the screening visit.
- The patient is an employee of the investigator or the institution with direct involvement in the trial or other trials under the direction of the investigator or their members.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Differences between inhaled glutathione and inhaled normal saline with respect to the area under the curve of FEV1 % predicted (forced expiratory volume in 1 second) within the period from baseline to week 24 (V5, EOT)
Time Frame: 24 weeks
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Treatment changes with respect to the variables:Spirometry,Peak flow,quality-of-life,Weight/ height,Percentage of neutrophils/other cell types (induced sputum),Induced sputum levels of glutathione/ inflammatory mediators,Pulmonary exacerbation
Time Frame: 0,4, 12, 24 weeks
|
0,4, 12, 24 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Matthias Griese, Prof., Dr. von Haunersches Kinderspital (University of Munich, Germany)
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Muko-D-GSH-4
- EudraCT-number: 2005-003870-88
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cystic Fibrosis
-
Hospital de Clinicas de Porto AlegreUnknownCystic Fibrosis | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in Children | Cystic Fibrosis With ExacerbationBrazil
-
University of Colorado, DenverCystic Fibrosis FoundationTerminatedCystic Fibrosis-related Diabetes | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in ChildrenUnited States
-
Royal College of Surgeons, IrelandThe Hospital for Sick Children; Imperial College London; Erasmus Medical Center; University College Dublin and other collaboratorsActive, not recruitingCystic Fibrosis | Adherence, Medication | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in Children | Cystic Fibrosis Liver DiseaseUnited Kingdom, Ireland
-
Herlev and Gentofte HospitalCopenhagen University Hospital, DenmarkActive, not recruitingMyocardial Infarction | Heart Diseases | Heart Failure | Stroke | Cystic Fibrosis | Heart Failure, Diastolic | Heart Failure, Systolic | Left Ventricular Dysfunction | Cystic Fibrosis-related Diabetes | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis of Pancreas | Cystic Fibrosis, Pulmonary | Cystic...Denmark
-
The Hospital for Sick ChildrenCanadian Cystic Fibrosis FoundationActive, not recruitingCystic Fibrosis | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in ChildrenCanada
-
Arrowhead PharmaceuticalsTerminatedCystic Fibrosis, PulmonaryAustralia, New Zealand
-
AzurRx SASCompletedCystic Fibrosis | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis of PancreasTurkey, Hungary
-
Dartmouth-Hitchcock Medical CenterTrustees of Dartmouth CollegeWithdrawnCystic Fibrosis-related Diabetes | Cystic Fibrosis Liver Disease | CF - Cystic FibrosisUnited States
-
University Hospital, BordeauxCompleted
-
University of PortsmouthUniversity Hospital Southampton NHS Foundation Trust; Loughborough University; Queen Alexandra HospitalTerminated
Clinical Trials on reduced glutathione sodium salt
-
Bastyr UniversityMichael J. Fox Foundation for Parkinson's ResearchCompletedParkinson's DiseaseUnited States
-
Nathalie JohnsonCompleted
-
The George InstituteUniversity of Abuja Teaching HospitalActive, not recruitingBlood PressureNigeria
-
University of North Texas, Denton, TXKirin Holdings Company, LimitedCompleted
-
The George InstitutePeking University; China Medical University, China; Northwestern University; Imperial... and other collaboratorsCompleted
-
University of WashingtonMichael J. Fox Foundation for Parkinson's ResearchCompleted
-
Abant Izzet Baysal UniversityCompleted
-
University College CorkCompletedElevated Blood PressureIreland
-
Serafino A. MarsicoFederico II UniversityUnknown
-
Bispebjerg HospitalCompleted